Consistently, another RNA-seq dataset from patients with advanced melanoma treated with ipilimumab followed by nivolumab (30) revealed an increase in USP22 transcripts in nonresponders compared with responders (Figure 6I), which were inversely correlated with B2M transcript levels (Figure 6I). This evidence concerns the gene B2M and melanoma.